These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1070 related articles for article (PubMed ID: 29808164)

  • 1. lncRNA-MEG3 Suppresses the Proliferation and Invasion of Melanoma by Regulating CYLD Expression Mediated by Sponging miR-499-5p.
    Long J; Pi X
    Biomed Res Int; 2018; 2018():2086564. PubMed ID: 29808164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Noncoding RNA Taurine-Upregulated Gene1 (TUG1) Promotes Tumor Growth and Metastasis Through TUG1/Mir-129-5p/Astrocyte-Elevated Gene-1 (AEG-1) Axis in Malignant Melanoma.
    Long J; Menggen Q; Wuren Q; Shi Q; Pi X
    Med Sci Monit; 2018 Mar; 24():1547-1559. PubMed ID: 29543785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis.
    Wu M; Huang Y; Chen T; Wang W; Yang S; Ye Z; Xi X
    J Cell Mol Med; 2019 Jan; 23(1):29-38. PubMed ID: 30565858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. lncRNA MEG3 modified epithelial-mesenchymal transition of ovarian cancer cells by sponging miR-219a-5p and regulating EGFR.
    Wang L; Yu M; Zhao S
    J Cell Biochem; 2019 Oct; 120(10):17709-17722. PubMed ID: 31161607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11.
    Liu Z; Chen JY; Zhong Y; Xie L; Li JS
    Braz J Med Biol Res; 2019; 52(10):e8631. PubMed ID: 31531526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1.
    Shen B; Zhou N; Hu T; Zhao W; Wu D; Wang S
    J Cell Physiol; 2019 Aug; 234(8):13464-13480. PubMed ID: 30624782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
    Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
    Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-338-5p promotes the growth and metastasis of malignant melanoma cells via targeting CD82.
    Long J; Luo J; Yin X
    Biomed Pharmacother; 2018 Jun; 102():1195-1202. PubMed ID: 29710538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling.
    Zhao M; Xin XF; Zhang JY; Dai W; Lv TF; Song Y
    Cancer Med; 2020 Feb; 9(3):1196-1208. PubMed ID: 31860169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer.
    Zhang W; Shi S; Jiang J; Li X; Lu H; Ren F
    Biomed Pharmacother; 2017 Jul; 91():312-319. PubMed ID: 28463794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study on the mechanism behind lncRNA MEG3 affecting clear cell renal cell carcinoma by regulating miR-7/RASL11B signaling.
    He H; Dai J; Zhuo R; Zhao J; Wang H; Sun F; Zhu Y; Xu D
    J Cell Physiol; 2018 Dec; 233(12):9503-9515. PubMed ID: 29968912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA FOXD3-AS1 promotes proliferation, invasion and migration of cutaneous malignant melanoma via regulating miR-325/MAP3K2.
    Chen X; Gao J; Yu Y; Zhao Z; Pan Y
    Biomed Pharmacother; 2019 Dec; 120():109438. PubMed ID: 31541886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA-MEG3 inhibits proliferation and metastasis by regulating miRNA-21 in gastric cancer.
    Dan J; Wang J; Wang Y; Zhu M; Yang X; Peng Z; Jiang H; Chen L
    Biomed Pharmacother; 2018 Mar; 99():931-938. PubMed ID: 29710493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1.
    Pu J; Wu X; Wu Y; Shao Z; Luo C; Tang Q; Wang J; Wei H; Lu Y
    Aging (Albany NY); 2021 Mar; 13(8):12207-12223. PubMed ID: 33952719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lncRNA HOXA11-AS promotes glioma cell growth and metastasis by targeting miR-130a-5p/HMGB2.
    Xu CH; Xiao LM; Liu Y; Chen LK; Zheng SY; Zeng EM; Li DH
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):241-252. PubMed ID: 30657566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway.
    Cheng J; Sun Y; Zhao H; Ren W; Gao D; Wang Z; Lv W; Dong Q
    PeerJ; 2023; 11():e16314. PubMed ID: 38047026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression.
    Zhang K; Guo L
    Gene; 2018 Jan; 641():272-278. PubMed ID: 29054757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-140-5p is negatively correlated with proliferation, invasion, and tumorigenesis in malignant melanoma by targeting SOX4 via the Wnt/β-catenin and NF-κB cascades.
    Zhao G; Yin Y; Zhao B
    J Cell Physiol; 2020 Mar; 235(3):2161-2170. PubMed ID: 31385607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p/EIF5A2 axis.
    Luan W; Ding Y; Yuan H; Ma S; Ruan H; Wang J; Lu F; Bu X
    J Exp Clin Cancer Res; 2020 May; 39(1):96. PubMed ID: 32466797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression.
    Zhang H; Cai Y; Zheng L; Zhang Z; Lin X; Jiang N
    J Cell Physiol; 2018 Oct; 233(10):6638-6648. PubMed ID: 29319165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.